1. Home
  2. FINV vs JANX Comparison

FINV vs JANX Comparison

Compare FINV & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinVolution Group

FINV

FinVolution Group

HOLD

Current Price

$4.38

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$15.88

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINV
JANX
Founded
2007
2017
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
975.7M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
FINV
JANX
Price
$4.38
$15.88
Analyst Decision
Strong Buy
Buy
Analyst Count
1
13
Target Price
$12.10
$47.00
AVG Volume (30 Days)
374.1K
688.7K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
6.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.58
N/A
P/E Ratio
$3.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$12.12
52 Week High
$9.73
$35.34

Technical Indicators

Market Signals
Indicator
FINV
JANX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
FINV
JANX

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: